Title : Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.

Pub. Date : 2017 Jul

PMID : 28218410






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the pivotal TEMPO 3:4 trial, the arginine vasopressin V2-receptor antagonist tolvaptan reduced the rate of kidney growth in patients with autosomal dominant polycystic kidney disease. Tolvaptan arginine vasopressin receptor 2 Homo sapiens